Welcome to our dedicated page for BRAINSTORM CELL THERAPEUTICS SEC filings (Ticker: BCLI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BRAINSTORM CELL THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BRAINSTORM CELL THERAPEUTICS's regulatory disclosures and financial reporting.
Brainstorm Cell Therapeutics Inc. reported continued operating losses while advancing its NurOwn® ALS program. For the six months ended June 30, 2026, the company recorded a net loss of $5.98 million, driven by $1.73 million in research and development and $3.93 million in general and administrative expenses. Operating cash outflow was $2.22 million, partially offset by $2.15 million of financing inflows from private placements and new short‑term borrowings.
The balance sheet is highly strained. As of June 30, 2026, Brainstorm held only $22 thousand in cash and cash equivalents and $209 thousand including restricted cash, against $12.39 million in current liabilities, resulting in total assets of $0.79 million and a stockholders’ deficit of $11.60 million. Management explicitly states that recurring losses, limited cash, and dependence on raising additional capital raise substantial doubt about the company’s ability to continue as a going concern.
Strategically, the company continues to focus on NurOwn for ALS. It has withdrawn its prior BLA after an FDA advisory committee voted that data did not demonstrate substantial evidence of effectiveness, but subsequently obtained FDA Special Protocol Assessment agreement and CMC alignment for a planned Phase 3b registrational trial intended to support a future marketing application.
BrainStorm Cell Therapeutics Inc. reported second quarter 2026 results and provided a corporate update centered on its NurOwn autologous stem cell platform for ALS and other neurodegenerative diseases. The company is completing preparations to initiate the Phase 3b ENDURANCE study of NurOwn in ALS under an FDA-agreed Special Protocol Assessment.
Peter Pitts, a former senior FDA official, has been appointed Executive Chairman with an active role in regulatory, operational, partnership and capital-markets initiatives. NurOwn has Orphan Drug designation in the U.S. and EU, with a completed Phase 3 ALS trial and a Phase 2 trial in progressive multiple sclerosis. BrainStorm is also advancing an allogeneic exosome-based platform and recently received a Notice of Allowance for a foundational exosome patent.
Financially, total assets were $788 thousand as of June 30, 2026, versus liabilities of $12,385 thousand, resulting in stockholders’ deficit of $(11,597) thousand. Cash and cash equivalents were $22 thousand$3,855 thousand (basic and diluted net loss per share of $0.35) compared with a net loss of $2,903 thousand a year earlier.
BrainStorm Cell Therapeutics reports significant leadership and compensation changes. The board appointed director Peter Pitts as Executive Chairman and Chief Strategic Regulatory and Policy Officer, granting him stock options for 900,000 common shares; he will not receive base salary, cash bonus, or director compensation. One-fourth of this option vests on July 24, 2027, with the remainder vesting in equal monthly installments over the following three years.
Professor Jacob Frenkel resigned as chairman and director, will serve as an advisor under a consulting agreement, and received 100,000 restricted stock units vesting in two tranches through April 24, 2027, along with accelerated vesting and extended exercise periods for his options; his resignation was not due to any disagreement. Executive Vice President and Chief Medical Officer Ibrahim Dagher resigned and will consult for one year under an agreement that treats his service as continued employment for equity awards and, upon successful completion, fully vests his outstanding equity and extends option exercise periods. A company press release highlights Pitts’s role in leading the planned NurOwn Phase 3b ALS trial under an FDA Special Protocol Assessment.
FRENKEL JACOB A reported acquisition or exercise transactions in this Form 4 filing.
BrainStorm Cell Therapeutics Inc. reported that director Jacob A. Frenkel received a grant of 100,000 restricted stock units (RSUs) representing common stock under a Consulting Agreement dated July 24, 2026 and the 2014 Global Share Option Plan. The RSUs vest 50% on October 24, 2026 and 50% on April 24, 2027, contingent on continued service. Following this equity award, his direct holdings are reported at 343,777 shares of common stock.
Brainstorm Cell Therapeutics Inc. reported that Executive Chairman Peter Joe Pitts received a grant of 900,000 stock options on July 24, 2026. The options have a $1.00 exercise price, are exercisable for 900,000 common shares, expire on July 24, 2036, and vest over 48 months subject to continued employment.
Brainstorm Cell Therapeutics director Peter Joe Pitts reported initial holdings of a stock option to buy common shares. The option covers 150,000 underlying shares of common stock at an exercise price of $0.68 per share and expires on May 25, 2036.
According to the disclosures, the option was granted under the company’s 2014 Stock Incentive Plan. It vests 50% on the grant date and 50% on the six-month anniversary of the grant, if Pitts continues serving the company through each vesting date.
Lebovits Chaim reported acquisition or exercise transactions in this Form 4 filing.
BrainStorm Cell Therapeutics President & CEO Chaim Lebovits reported an award of 1,800,000 shares of common stock in the form of restricted stock units under the company’s equity plan. The RSUs vest 50% on the February 26, 2026 grant date and 50% on the six‑month anniversary, contingent on his continued employment. Following this compensation grant, he holds 2,000,960 shares of common stock directly.
Yablonka Uri reported acquisition or exercise transactions in this Form 4 filing.
BrainStorm Cell Therapeutics executive Uri Yablonka received a grant of 150,000 shares of common stock in the form of restricted stock units. According to the award terms, 50% of the RSUs vest on the grant date and the remaining 50% vest six months later, contingent on continued employment. Following this compensation grant, Yablonka holds 218,464 shares directly.
Patlis Alla reported acquisition or exercise transactions in this Form 4 filing.
Brainstorm Cell Therapeutics Inc. reported that officer Alla Patlis received a grant of 100,000 shares of Common Stock in the form of restricted stock units (RSUs) at no cash cost per share. Following this award, Patlis directly holds 144,349 shares.
According to the terms, 50% of the RSU award vests on the grant date and the remaining 50% vests on the six‑month anniversary of the grant, as long as Patlis remains employed by the company through each vesting date. This filing reflects a compensation-related equity grant rather than an open‑market share purchase or sale.